Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
New York City Health and Hospitals Corporation · American Academy of Child and Adolescent Psychiatry · +6 more institutions
Abstract
Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression.
In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were randomly assigned and received treatment with single-dose psilocybin (0.3 mg/kg) or niacin, both in conjunction with psychotherapy. The primary outcomes were anxiety and depression assessed between groups prior to the crossover at 7 weeks.
Citation impact
- FWCI
- 94.60
- Percentile
- 100%
- References
- 91
Authors
13- SRStephen RossCorresponding
New York City Health and Hospitals Corporation, American Academy of Child and Adolescent Psychiatry, NYU Langone Health, Bellevue Hospital Center, Center for Clinical Research (United States), New York University, New York College of Health Professions
- APAnthony P. Bossis
Bellevue Hospital Center, Center for Clinical Research (United States), New York University, New York College of Health Professions
- JGJeffrey Guss
Bellevue Hospital Center, Center for Clinical Research (United States), New York University, New York College of Health Professions
- GAGabrielle Agin-Liebes
Palo Alto University
- TCTara C. Malone
New York University
Topics & keywords
- Psilocybin
- Anxiety
- Psychiatry
- Anxiolytic
- Psychology
- Randomized controlled trial
- Depression (economics)
- Placebo